Basilea received a $10 million milestone payment related to the approval of the antifungal agent Cresemba® (isaconazole) in China – QNT Press Release


  • China National Medical Products Administration (NMPA) grants Basilea’s licensing partner Pfizer the approval of Cresemba’s drug in China

According to the art special announcement. 53 LR

December 21, 2021, Basel, Switzerland

Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company dedicated to meeting the needs of patients with infectious diseases and cancer, today announced its licensing partner Pfizer Inc. (NYSE:PTFE, “Pfizer”)), has obtained a drug approval certificate from the National Medical Products Administration (NMPA) of China for the oral preparation of its antifungal agent Cresemba® (Isaconazole). After obtaining this authorization, oral Cresemba has now been approved in China for the treatment of adult patients with invasive mucormycosis. The grant of approval for the drug triggered Pfizer’s $10 million milestone payment to Basilea. Intravenous preparations for the treatment of invasive mucormycosis are currently being reviewed under a separate marketing authorization application.

In October 2020, Pfizer also submitted an application for marketing authorization for oral and intravenous Cresemba for the treatment of invasive aspergillosis. These applications are undergoing regulatory review by the NMPA Drug Evaluation Center.

David Veitch, CEO of Basilea, said: “We congratulate our partner Pfizer (Pfizer) for approving Cresemba to treat adult patients with invasive mucormycosis in China. Invasive fungal infections, such as mucormycosis, can be harmful to patients if left untreated. Posing a serious threat. With this approval, Chinese patients suffering from mucormycosis will now be able to receive treatments that help address their unmet needs. China is a very important commercial market for Cresemba, accounting for approximately 20% of global sales of new antifungal drugs. “

The licensing agreement between Basilea and Pfizer covers Europe (excluding the Nordic countries), Russia, Turkey and Israel, as well as China (including Hong Kong and Macau) and…

The full story can be found on


Source link

Recommended For You

About the Author: News Center